Vivo Capital Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
44

- Investments
-
320
- Portfolio
-
81
- Exits
-
189

Vivo Capital General Information
Description
Founded in 1996, Vivo Capital is a venture capital firm based in Palo Alto, California. The firm seeks to invest in biopharmaceuticals, specialty pharmaceuticals, medical devices, and other subsectors of healthcare and life sciences companies.
Contact Information
Investor Status
Actively Seeking New Investments
Trade Association
Principles for Responsible Investment (PRI)
Primary Investor Type
Venture Capital
Other Investor Types
Growth/Expansion
Primary Office
- 192 Lytton Avenue
- Palo Alto, CA 94301
- United States
+1 (650) 000-0000
Vivo Capital Investments (320)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
---|---|---|---|---|---|---|
Ronovo Surgical | 21-Dec-2022 | Early Stage VC | Surgical Devices | Pre-Clinical Trials | 000000 00 00.0 | |
000000000 | 06-Dec-2022 | 00000 00000 | 00000 | Drug Discovery | Clinical Trials - Phase 3 | |
000000 00000000000 | 29-Nov-2022 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 000000 00 00.0 |
00000 000000000000 | 15-Nov-2022 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | |
00000 | 07-Nov-2022 | 00000 00000 | 00000 | Biotechnology | Clinical Trials - Phase 2 | 000000 00 00.0 |
0000000 0000000000 | 02-Nov-2022 | 0000 | 0000 | Drug Discovery | Generating Revenue | |
00000000 000 | 24-Oct-2022 | 00000 00000 | 0000 | Drug Delivery | Pre-Clinical Trials | |
0000000 0000000000 | 12-Oct-2022 | 0000 | 0000 | Drug Discovery | Generating Revenue | |
Neocis | 23-Sep-2022 | Later Stage VC | 0000 | Surgical Devices | Generating Revenue | |
Ventyx Biosciences | 20-Sep-2022 | PIPE | 00000 | Drug Discovery | Generating Revenue |
Vivo Capital Exits (189)
Company Name | Exit Date | Exit Type | Exit Size |
---|---|---|---|
LEPU ScienTech | 07-Nov-2022 | IPO | 000.00 |
000000000 | 26-Jul-2022 | 000000000000000000 | |
000000 | 06-May-2022 | 000 | 00000 |
000000 | 30-Dec-2021 | 000000 0000000000 | 0000 |
00 0000000 | 05-Nov-2021 | 000 | 00000 |
0000000000 | 02-Nov-2021 | 000000 00 000000 | |
000000 00000000000 | 21-Oct-2021 | 000 | 00000 |
00000 000000000000 | 10-Sep-2021 | 000000 0000000000 | 0000 |
Aadi Bioscience | 27-Aug-2021 | Reverse Merger | |
Sera Prognostics | 15-Jul-2021 | IPO | 0000 |
Vivo Capital Fund Performance
Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
---|
Vivo Capital Investments by Industry, Year, and Region
Vivo Capital Team (69)
Name | Title | Deals | Funds | Boards | Office |
---|---|---|---|---|---|
Shan Fu | Co-Chief Executive Officer, Chief Executive Officer of Greater China & Managing Partner | 00 | 0 | 0 | Beijing, China |
Daisy Xu | Managing Director | Palo Alto, CA | |||
David Liu Ph.D | Managing Director | Palo Alto, CA | |||
Gaurav Aggarwal MD | Managing Director | 0 | 0 | 0 | Palo Alto, CA |
Hao Dong | Managing Director | Palo Alto, CA |
Vivo Capital Co-Investors (282)
Name | With | Exits | Lead Partner | Series | Industry |
---|---|---|---|---|---|
venBio | 12 | 0 | 0 |
![]() |
![]() |
Cormorant Asset Management | 00 | 0 | 0 |
![]() |
![]() |
Logos Capital | 00 | 0 | 0 |
![]() |
![]() |
OrbiMed | 00 | 0 | 0 |
![]() |
![]() |
RA Capital Management | 00 | 0 | 0 |
![]() |
![]() |